On July 13, Genscript Biotech rose 5.27% in regular trading, trading at HK$14.66/share, with turnover of approximately HK$81.69 million.

On the news front, the CXO sector's mid-year earnings realization window has opened, with multiple brokerages highlighting a significant acceleration in new order signings across the industry. After the gradual digestion of earlier low-price orders, the sector's revenue and profit dual inflection point has been confirmed. Data shows that 22 listed CXO companies reported Q1 revenue and net profit growth of 18.6% and 21.9% year-over-year respectively, with domestic CXO firms seeing robust orders and both volume and pricing improvements, as financial statement improvements are being progressively realized.

Genscript Biotech is an investment holding company primarily engaged in life sciences research products and services, with businesses spanning gene synthesis, biologics development, industrial synthetic biology, and cell therapy. Its associate Legend Biotech's CARVYKTI generated approximately US$597 million in net trade sales in Q1, up 62% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)